Cargando…

Impact of Ezetimibe on New‐Onset Diabetes: A Substudy of IMPROVE‐IT

Detalles Bibliográficos
Autores principales:	Shah, Nishant P., McGuire, Darren K., Cannon, Christopher P., Giugliano, Robert P., Lokhnygina, Yuliya, Page, Courtney B., Tershakovec, Andrew M., Braunwald, Eugene, Blazing, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356081/ https://www.ncbi.nlm.nih.gov/pubmed/37345760 http://dx.doi.org/10.1161/JAHA.122.029593

Ejemplares similares

Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT
por: Giugliano, Robert P., et al.
Publicado: (2020)

Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT
por: Fordyce, Christopher B., et al.
Publicado: (2022)

Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long‐Term Follow‐Up After Acute Coronary Syndromes
por: Fanaroff, Alexander C., et al.
Publicado: (2017)

Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
por: Kato, Eri Toda, et al.
Publicado: (2017)

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial
por: Guyton, John R., et al.
Publicado: (2012)

Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients
por: Abramson, Beth L, et al.
Publicado: (2011)

A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia
por: Saito, Itori, et al.
Publicado: (2015)

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
por: Le, Ngoc‐Anh, et al.
Publicado: (2013)

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk
por: Rosen, Jeffrey B., et al.
Publicado: (2015)

Relationships Between Metabolic Syndrome and Other Baseline Factors and the Efficacy of Ezetimibe/Simvastatin and Atorvastatin in Patients With Type 2 Diabetes and Hypercholesterolemia
por: Goldberg, Ronald B., et al.
Publicado: (2010)

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
por: Foody, JoAnne M, et al.
Publicado: (2013)

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
por: Stevens, Susanna R., et al.
Publicado: (2022)

Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
por: Le, Ngoc‐Anh, et al.
Publicado: (2015)

Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]
por: Cherney, David Z. I., et al.
Publicado: (2022)

Ezetimibe therapy: mechanism of action and clinical update
por: Phan, Binh An P, et al.
Publicado: (2012)

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
por: Nauck, Michael A., et al.
Publicado: (2019)

Fungal biotransformation of ezetimibe
por: Pervaiz, Irfan, et al.
Publicado: (2014)

The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years
por: Ben-Yehuda, Ori, et al.
Publicado: (2011)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years
por: Constance, Christian, et al.
Publicado: (2014)

Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
por: Lee, Jun-beom, et al.
Publicado: (2017)

Ezetimibe: An Unusual Suspect in Angioedema
por: Lu, Tiffany, et al.
Publicado: (2020)

Synthesis and Modeling of Ezetimibe Analogues
por: Salgado, Mateo M., et al.
Publicado: (2021)

Ezetimibe and Cancer: Is There a Connection?
por: Gu, Jia, et al.
Publicado: (2022)

Effect of PCSK9 Inhibition on the Plasma Proteome: A SPIRE SubStudy
por: Kraaijenhof, Jordan M., et al.
Publicado: (2023)

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
por: Kato, Eri Toda, et al.
Publicado: (2022)

Impact on urinary oxalate levels with use of ezetimibe
por: Trautman, Christopher L., et al.
Publicado: (2021)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Liver Injury Associated With Ezetimibe Monotherapy
por: Kanagalingam, Tharsan, et al.
Publicado: (2020)

Cilostazol and Probucol for Cognitive Decline after Stroke: A Cognitive Outcome Substudy of the PICASSO Trial
por: Lim, Jae-Sung, et al.
Publicado: (2021)

Repolarization parameters and ventricular arrhythmias in Takotsubo syndrome: A substudy from the RETAKO national registry
por: Vazirani, Ravi, et al.
Publicado: (2023)

Comparison of regression imputation methods of baseline covariates that predict survival outcomes
por: Solomon, Nicole, et al.
Publicado: (2020)

Effect of Ezetimibe on Insulin Secretion in db/db Diabetic Mice
por: Zhong, Yong, et al.
Publicado: (2012)

Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
por: Segar, Matthew W., et al.
Publicado: (2020)

Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease
por: Kovach, Christopher P., et al.
Publicado: (2023)

Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study
por: Correia, Luis C. L.
Publicado: (2016)

IMPROVE-IT: A Final Closure to Carcinogenicity of Ezetimibe?
por: Lewis, Eldrin F., et al.
Publicado: (2020)

Validation of the WATCH‐DM and TRS‐HF(DM) Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis
por: Segar, Matthew W., et al.
Publicado: (2022)

2159. Methodological Threats to the Standardized Infection and Standardized Antimicrobial Administration Ratios
por: Lofgren, Eric, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qoeoluhpdvmp6fl3cn9mfea96n